AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01121848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Pharmaceutical form: vials of 5 g/100mL Route of administration: IV~Dose regimen:
Study NCT05258448 — intervention group
Intervention type: OTHER
Intervention: Chemoradiotherapy
Description: Cardiac Magnetic Resonance scan and ECG
Study NCT01450696 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Herceptin
Description: Herceptin will be administered at a loading dose of 8 mg/kg on Day 1 of Cycle 1 followed by 6 or 10 mg/kg (depending upon treatment assignment) q3w from Day 1 of Cycle 2 until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason.
Study NCT03070639 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safe Sleep Intervention
Description: A health educator will visit participant during their 2-week well visit in the clinic, to deliver a tailored intervention based on the baby's sleep practices. Participant will also receive a free pack'n play, sleep sack, and educational resources on safe sleep.
Study NCT03070639 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Scald Prevention Intervention
Description: A health educator will visit participant during their 2-week well visit in the clinic, to deliver a tailored intervention based on practices regarding scald risks in the home. Participant will also receive a bath thermometer, candy/frying thermometer, and educational resources on scald prevention.
Study NCT01697423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: platelet-rich plasma
Study NCT01697423 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: durolane
Study NCT02147210 — intervention group
Intervention type: OTHER
Intervention: biological analysis
Study NCT01167101 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rebamipide
Description: Rebamipide 100mg Tid for 28days
Study NCT01167101 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: pantoprazole
Description: pantoprazole 40mg qd for 28days
Study NCT01167101 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pantoprazole
Description: pantoprazole 40mg qd for 28days
Study NCT03780907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2007
Description: 2 mg of E2007 was administered by mouth once daily.
Study NCT03780907 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily of oral tablet formulation to be taken in the morning, one hour before breakfast, with a glass of water.
Study NCT05036551 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Kellgren Lawrence classification
Description: The Kellgren Lawrence classification was used in the radiological evaluation. It is a classification method used in the staging of knee osteoarthritis. Five stages were defined according to the anteroposterior X-ray.(Stage 0-5)
Study NCT02394704 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sensory attention training
Description: Participants will be instructed to attend to sensory stimuli and to press a button as quickly and accurately as possible while ruminating. Stimuli will consist of vibration via a wearable subwoofer or non-painful electrical muscle stimulation (10Hz biphasic current with a pulse width of 200us with rectangular 2 electrodes placed on the back near the shoulders) or vibratory stimulation with a vibroacoustic element placed on the back near the shoulders. Up to four sessions will be approximately 45 minutes, over the course of two weeks.
Study NCT02394704 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sensory attention training
Description: Participants will be instructed to attend to sensory stimuli and to press a button as quickly and accurately as possible while ruminating. Stimuli will consist of vibration via a wearable subwoofer or non-painful electrical muscle stimulation (10Hz biphasic current with a pulse width of 200us with rectangular 2 electrodes placed on the back near the shoulders) or vibratory stimulation with a vibroacoustic element placed on the back near the shoulders. Up to four sessions will be approximately 45 minutes, over the course of two weeks.
Study NCT01336452 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: DCE MRI
Description: DCE (dynamic contrast enhanced) MRI will be obtained just before CCRTx and immediately after finishing CCRTx with 0.1mmol/kg of MR contrast media; CEUS will be obtained just before CCRTx, immediately after finishing CCRTx, and 1 month after CCRTx with 2.4 mL of SonoVue. Blood sampling for biomarker analysis will be performed just before CCRTx, immediately after finishing CCRTx, and 1 month after CCRTx (20mL)
Study NCT03968978 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tezepelumab (APFS)
Description: Tezepelumab subcutaneous injection, administered by Accessorized pre-filled syringe (APFS).
Study NCT03968978 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tezepelumab (AI)
Description: Tezepelumab subcutaneous injection, administered by Autoinjector (AI) device.
Study NCT00991705 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Atorvastatin
Study NCT00991705 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fimasartan
Study NCT02045589 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: VCN-01
Description: Genetically modified human adenovirus encoding human PH20 hyaluronidase
Study NCT02045589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m2 intravenous administration
Study NCT02045589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane®
Description: 125 mg/m2 intravenous administration
Study NCT01659775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sancuso patch
Description: Eligible patients were randomized to Sancuso patch or Zofran groups and received the assigned treatment for 5days.~Experimental arm: Sancuso patch (34.3mg) applied to upper, outer arm 2days (48-24hours) prior to start of chemotherapy.
Study NCT01659775 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zofran inj.+Zofran tab.
Description: Eligible patients were randomized to Sancuso patch or Zofran groups and received the assigned treatment for 5days.~Active Comparator arm: administered intravenously (24mg or 32mg) on Day 1 of chemotherapy and orally (8mg bid) on Day 2-5.
Study NCT02144051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5312
Description: AZD5312 is a generation 2.5 antisense oligonucleotide (ASO) which is designed with the purpose of specifically suppressing human Androgen Receptor (AR) expression, thereby providing potential therapeutic benefit for the treatment of mCRPC and other AR-dependent cancers.
Study NCT00260494 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: standardized acupuncture intended to improve blood flow and reduce edema to lower extremity.
Study NCT00260494 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham acupuncture
Description: standardized sham acupuncture at same sites as acupuncture.
Study NCT01325415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-118
Description: 25 mg tablet
Study NCT01325415 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: moxifloxacin
Description: 400 mg tablet
Study NCT01325415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: tablet
Study NCT01325415 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablet
Study NCT03723759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faster Aspart 200 U/mL
Description: A single dose (0.15 U/kg) of five formulations of fast-acting insulin aspart 200 U/mL (formulations A, B, C, D, E) in a sequential manner via subcutaneous injection.
Study NCT03723759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faster aspart 100 U/mL
Description: A single dose (0.15 U/kg) of fast-acting insulin aspart 100 U/mL via subcutaneous injection.
Study NCT02728336 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac MRI
Study NCT03224572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: high-dose vitamin C 30gm
Description: High-dose vitamin C 30 gm in 500 ml normal saline, once per week, and total 4-week treatment.
Study NCT03224572 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: 500ml normal saline, once per week, and total 4-week treatment
Study NCT03224572 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: normal saline
Description: 500ml normal saline, once per week, and total 4-week treatment
Study NCT04362787 — intervention group
Intervention type: DEVICE
Intervention: High pressure non invasive ventilation in acute hypercapnic respiratory failure
Description: Usage of High pressure non invasive ventilation in acute hypercapnic respiratory failure
Study NCT04445324 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transitional Online Peer Support Group (n=20)
Description: Trained Peer Support Workers (PSWs) from the Quebec Association of PSWs will organize and facilitate two series (one per condition) of 10 co-learning recovery workshops in a manner to simulate a typical peer support group. The difference of these transitional peer support groups to real community-based peer support groups is that (A) they will be facilitated by trained PSW, (B) they will have a personal-civic recovery focus, and (C) they will have a fixed, predetermined duration (10 weekly 60 to 90-minute online workshops). Typical Peer support groups bring together people who have similar concerns so they can explore solutions to overcome shared challenges and feel supported by others with similar experiences and who may better understand each other's situation. Peer support groups should ideally be independent from mental health and social services, although some services may facilitate and encourage the creation of (transitional) peer support groups, as is the case here. (WHO)
Study NCT04445324 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group (pharmacotherapy and/or psychotherapy, n=10)
Description: When individuals show up at the Emergency Department (T1) of the Montreal Mental Health University Institute, they are evaluated by the Evaluation and Liaison Module during their hospital stay when they are hospitalized. A diagnostic is established or confirmed by psychiatrists on the ward, and coded according to the World Health Organisation International Classification of Disease (ICD-10). According to these diagnoses, after discharge (T2) they are referred to a specialized outpatient clinic for an appointment (T3). Whether for (a) psychotic disorders or for (b) anxiety and mood disorders, pharmacotherapy or psychotherapy, or a combination of both, are then offered in accordance with guidelines of the Royal College of Physicians and Surgeons of Canada.
Study NCT04445324 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Group (pharmacotherapy and/or psychotherapy, n=10)
Description: When individuals show up at the Emergency Department (T1) of the Montreal Mental Health University Institute, they are evaluated by the Evaluation and Liaison Module during their hospital stay when they are hospitalized. A diagnostic is established or confirmed by psychiatrists on the ward, and coded according to the World Health Organisation International Classification of Disease (ICD-10). According to these diagnoses, after discharge (T2) they are referred to a specialized outpatient clinic for an appointment (T3). Whether for (a) psychotic disorders or for (b) anxiety and mood disorders, pharmacotherapy or psychotherapy, or a combination of both, are then offered in accordance with guidelines of the Royal College of Physicians and Surgeons of Canada.
Study NCT03290898 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High Intensity Interval Training
Description: Training (HIIT)
Study NCT02314416 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Amniotic Stem Cells and Collagen Matrix
Description: Nucel will be applied in between two pieces of collagen matrix'. The NuCel-impregnated collagen matrix will be placed over a clean, debrided wound.
Study NCT02314416 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Amniotic Stem Cells and Collagen Matrix
Description: Nucel will be applied in between two pieces of collagen matrix'. The NuCel-impregnated collagen matrix will be placed over a clean, debrided wound.
Study NCT00672867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clevudine
Description: 30mg
Study NCT00672867 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adefovir dipivoxil
Description: 10mg
Study NCT02090569 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional micro-Doppler Sonography (fmDS)
Description: 1. Craniotomy according to MRI images~2. Dura opening~3. Sulcal Localization using neuronavigation~4. Functional micro-Doppler Sonography including morphologic (Bmode) and functional measurement of the cerebral blood volume dynamics at high spatio-temporal resolution (100µm-20ms) using high-frequency (15MHz) ultrasound. At least 5 2-minute periods of spontaneous data will be recorded with a sampling rate for data acquisition of 15KHz and highpass filter of 10 to 70 Hz.~5. Exeresis of the dysplasic tissue~6. Control using fmDS before wound closure
Study NCT02197845 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigator
Description: A specially trained (SCD knowledgable) Patient Navigator will act as a liaison who assists participants in increasing adherence to HU through disease education, addressing barriers to care and improving adherence to HU. PN utilize various techniques geared toward the individual patients needs. Interventions utilized by a PN include improving disease management skills, educational materials about disease, HU adherence, motivational interviewing, care coordination and social support.
Study NCT02197845 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recruitment into Specialty Care
Description: A specially trained (SCD knowledgeable) Patient Navigator will act as a liaison to participants in increasing adherence to Hydroxyurea. Interventions utilized by a PN include teaching disease management skills, addressing barriers to care, disease education, HU management, motivational interviewing, care coordination and social support.
Study NCT04118166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab 1 mg/kg, injection
Study NCT04118166 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoablation
Description: Cryoablation of the tumors occur between investigational agent treatment Cycles 1 and 2, and will be performed according to standard procedures
Study NCT04118166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 3 mg/kg, injection
Study NCT04013334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTG201
Description: MTG201, 3 x 10E12 vp delivered by intratumoral injection on days 1, 8, 22 and 50
Study NCT04013334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab Injection [Opdivo]
Description: Nivolumab 480 mg by IV infusion every 4 weeks
Study NCT03413085 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: soft contact lens
Description: Group A~Group B
Study NCT04041219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Recommended starting dose will be in accordance with the established protocol (0.04 mg/kg/dose of ideal body weight), initially administered sublingually for four consecutive doses.
Study NCT04041219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Recommended starting dose will be in accordance with the established protocol (0.04 mg/kg/dose of ideal body weight), oral administration after sublingual four consecutive doses
Study NCT01880736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Individual dose adjusted once weekly. IDeg (100 U/mL, 3 mL FlexTouch® pen PDS290) to be administered under the skin OD with the option to vary time of administration within a window of plus/minus 8 hours. A maximum of 3 pre-trial OADs are allowed during the trial at an unchanged, stable dose level and dosing frequency.
Study NCT00949897 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biofoam
Description: Device
Study NCT00949897 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Iliac Crest Allograft with locked plate
Study NCT00468182 — intervention group
Intervention type: DRUG
Intervention: Interferon-beta 1b (Betaseron)
Description: Treatment of patients with FDA-approved Rx
Study NCT03155529 — intervention group
Intervention type: PROCEDURE
Intervention: radical hysterectomy
Description: A standard radical hysterectomy with lymphadenectomy was performed. Static and dynamic MRI were performed. A suggested urodynamic examination was done according to the ICS. A 3D reconstruction technique was used to construct the 3D model of the pelvis, pelvic floor muscle, pelvic organ such as bladder and urethral.
Study NCT02814240 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NMR
Study NCT02814240 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood samples
Study NCT02814240 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fibroscan
Study NCT04163861 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 2d speckle tracking echocardiography
Description: 2d speckle tracking echocardiography
Study NCT04163861 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: serum BNP level
Description: serum BNP level of HFpEF study subjects
Study NCT03724058 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trident® II Clusterhole HA Acetabular Shell
Description: Hip arthroplasty
Study NCT03724058 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Trident® Hemispherical Acetabular Shell
Description: Hip arthroplasty
Study NCT03647345 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-frequency rTMS on left DLPFC+anodal tDCS on right DLPFC
Description: 10Hz rTMS over the left DLPFC and anodal tDCS over the right DLPFC are simultaneously stimulated.
Study NCT03647345 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-frequency rTMS on left DLPFC+cathodal tDCS on right DLPFC
Description: 10Hz rTMS over the left DLPFC and cathodal tDCS over the right DLPFC are simultaneously stimulated.
Study NCT03647345 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High-frequency rTMS on left DLPFC+sham tDCS on right DLPFC
Description: 10Hz rTMS over the left DLPFC and sham tDCS (no stimulation) over the right DLPFC are simultaneously stimulated.
Study NCT01880736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Individual dose adjusted once weekly. IDeg (100 U/mL, 3 mL FlexTouch® pen PDS290) to be administered under the skin OD at the same time each day. A maximum of 3 pre-trial OADs are allowed during the trial at an unchanged, stable dose level and dosing frequency.
Study NCT04261751 — intervention group
Intervention type: OTHER
Intervention: Clinician Questionnaire
Description: Nurses will take the Clinician Questionnaire electronically
Study NCT02302001 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silicone Implant
Study NCT03086889 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immersion virtual reality (VR)-based rehabilitation
Description: Intervention group received VR-based rehabilitation,including Virtual kitchen and so on.The patients took part in the exercise program for 30 minutes each day, five times per week, for 3 weeks. All subjects received physiotherapy, which accounts for an average of 30 minutes of physiotherapy per day on tolerance.
Study NCT03086889 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: traditional rehabilitation training
Description: The traditional rehabilitation training included occupational therapy and physical therapy, patients took part in the traditional rehabilitation training for 60 minutes each day, five times per week, for 3 weeks.
Study NCT01417273 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: vitamin A
Description: 1 cap vitamin A 25000 IU/day for 6 months and 10000 IU/day for next 6 months
Study NCT04074967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase Ib ARRY-614 + nivolumab
Description: ARRY-614 continuously in 4-week cycles (± 3 days). Nivolumab will be dosed according to FDA-approved dosing schedule.
Study NCT04074967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase Ib ARRY-614 + nivolumab+ipilimumab
Description: ARRY-614 continuously in 4-week cycles (± 3 days). Nivolumab will be dosed according to FDA-approved dosing schedule. Ipilimumab therapy will be dosed according to FDA-approved dosing schedule.
Study NCT04074967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase II ARRY-614 + nivolumab
Description: Recommended Phase II dose of ARRY-614 (to be determined) daily in 4-week cycles (± 3 days).~Nivolumab will be dosed according to FDA-approved dosing schedule.
Study NCT04074967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase II ARRY-614 + nivolumab+ipilimumab (melanoma)
Description: Recommended Phase II dose of ARRY-614 (to be determined) daily in 4-week cycles (± 3 days).~Nivolumab will be dosed according to FDA-approved dosing schedule. Ipilimumab therapy will be dosed according to FDA-approved dosing schedule.
Study NCT02292082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Study NCT02292082 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine